NURIX THERAPEUTICS, INC. Cash and Restricted Cash
NURIX THERAPEUTICS, INC. (NRIX) had Cash and Restricted Cash of $68.65 million as of 2026-05-31, per its 10-Q filed 2026-07-09.
Financial Statements › Cash Flow › Cash
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents · last filed 2026-07-09
- 2026-05-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $68.65M.
- 2026-02-28: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $72.16M.
- 2025-11-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $247.93M.
- 2025-08-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $79.41M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents as first filed |
|---|---|---|
| 2026-05-31 | $68.65M 10-Q · filed 2026-07-09 | |
| 2026-02-28 | $72.16M 10-Q · filed 2026-04-08 | |
| 2025-11-30 | $247.93M 10-Q · filed 2026-07-09 | |
| 2025-08-31 | $79.41M 10-Q · filed 2025-10-09 | |
| 2025-05-31 | $85.16M 10-Q · filed 2026-07-09 | |
| 2025-02-28 | $76.82M 10-Q · filed 2026-04-08 | |
| 2024-11-30 | $110.90M 10-Q · filed 2026-07-09 | |
| 2024-08-31 | $99.94M 10-Q · filed 2025-10-09 | |
| 2024-05-31 | $117.69M 10-Q · filed 2025-07-09 | |
| 2024-02-29 | $50.71M 10-Q · filed 2025-04-08 | |
| 2023-11-30 | $55.53M 10-Q · filed 2025-10-09 | |
| 2023-08-31 | $43.20M 10-Q · filed 2024-10-11 | |
| 2022-11-30 | $65.38M 10-Q · filed 2024-10-11 | |
| 2022-08-31 | $47.56M 10-Q · filed 2022-10-06 | |
| 2022-05-31 | $41.53M 10-Q · filed 2022-07-07 | |
| 2022-02-28 | $78.78M 10-Q · filed 2022-04-08 | |
| 2021-11-30 | $80.51M 10-K · filed 2022-01-28 | |
| 2021-08-31 | $147.44M 10-Q · filed 2022-10-06 | |
| 2021-05-31 | $188.21M 10-Q · filed 2022-07-07 | |
| 2021-02-28 | $126.38M 10-Q · filed 2022-04-08 | |
| 2020-11-30 | $119.36M 10-K · filed 2022-01-28 | $119.53M 10-K · filed 2021-02-16 |
| 2020-08-31 | $265.53M 10-Q · filed 2021-10-14 | $265.70M 10-Q · filed 2020-10-14 |
| 2020-05-31 | $159.33M 10-Q · filed 2021-07-13 | |
| 2020-02-29 | $56.41M 10-Q · filed 2021-04-13 | |
| 2019-11-30 | $34.82M 10-K · filed 2022-01-28 | $34.99M 10-Q · filed 2020-10-14 |
| 2019-08-31 | $52.02M 10-Q · filed 2020-10-14 | |
| 2018-11-30 | $25.76M 10-Q · filed 2020-10-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |